Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML
| Autor: | Camino Estivill, Anna Aventin, J. Bargay, Josep M Marti-Tutusaus, Jordi Esteve, Mar Tormo, Andreu Llorente, Inmaculada Heras, Josep-Maria Ribera, Montserrat Hoyos, de Llano Mp, Maite Carricondo, Josep F. Nomdedeu, David Gallardo, Elena Bussaglia, Antoni Garcia, Salut Brunet, Olga Salamero, Rafael F. Duarte, Jordi Sierra |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male congenital hereditary and neonatal diseases and abnormalities Cancer Research Neoplasm Residual Adolescent Gene Dosage Antineoplastic Agents Biology urologic and male genital diseases Polymerase Chain Reaction Immunophenotyping Young Adult Bone Marrow hemic and lymphatic diseases medicine Biomarkers Tumor Humans WT1 Proteins Aged Neoplasm Staging Retrospective Studies urogenital system Remission Induction Hematology Middle Aged Prognosis female genital diseases and pregnancy complications Consolidation Chemotherapy Survival Rate Leukemia Myeloid Acute medicine.anatomical_structure Oncology Immunology Female Bone marrow Neoplasm Recurrence Local Follow-Up Studies |
| Zdroj: | Leukemia. 27(11) |
| ISSN: | 1476-5551 |
| Popis: | We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A cutoff value of 5065 copies at diagnosis identified two prognostic groups (overall survival (OS): 44 ± 3 vs 36 ± 3%, P=0.023; leukemia-free survival (LFS): 47 ± 3 vs 36 ± 4%, P=0.038; and cumulative incidence of relapse (CIR): 37 ± 3 vs 47 ± 4%, P=:0.043). Three groups were identified on the basis of WT1 levels post-induction: Group 0 (WT1 between 0 and 17.5 copies, 134 patients, OS: 59 ± 4%, LFS:59 ± 4% and CIR: 26 ± 4%); Group 1 (WT1 between 17.6 and 170.5 copies, 160 patients, OS: 48 ± 5%, LFS:41 ± 4% and CIR: 45 ± 4%); and Group 2 (WT1170.5 copies, 71 patients, OS: 23 ± 6%, LFS: 19 ± 7% and CIR: 68 ± 8%) (P0.001). Post-intensification samples distinguished three groups: patients with WT1100 copies (47 patients, 16%); an intermediate group of patients with WT1 between 10 and 100 copies (148 patients, 52%); and a third group with WT110 copies (92 patients, 32%). Outcomes differed significantly in terms of OS (30 ± 7%, 59 ± 4%, 72 ± 5%), LFS (24 ± 7%, 46 ± 4%, 65 ± 5%) and relapse probability (CIR 72 ± 7%, 45 ± 4%, 25 ± 5%), all P0.001. WT1 levels in bone marrow assayed using the standardized ELN method provide relevant prognostic information in de novo AML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|